Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems

Scheifes, Arlette; Stolker, Joost J.; Egberts, Toine C. G.; Nijman, Henk; Heerdink, Eibert R.

doi:10.1111/j.1365-2788.2010.01353.x

Cited by 25 publications

(13 citation statements)

References 115 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent review outlined that trials in this area generally involved too low numbers of patients with too much heterogeneity to draw conclusions (Scheifes et al . ).…”

Section: Introductionmentioning

confidence: 97%

Effects of controlled discontinuation of long‐term used antipsychotics for behavioural symptoms in individuals with intellectual disability

Kuijper

Evenhuis

Minderaa

et al. 2012

J intellect Disabil Res

View full text Add to dashboard Cite

Background Antipsychotics are frequently and often long-term used for challenging behaviour in persons with intellectual disability (ID), but the evidence base for this is meagre. As these agents may cause harmful side effects, discontinuation should be considered. Previous studies regarding discontinuation of long-term used antipsychotics mostly were uncontrolled and involved small numbers. The primary objective was to investigate the effects of controlled discontinuation of antipsychotics prescribed for challenging behaviour. Secondary objectives were to compare the results of two discontinuation time schedules, to compare groups of participants who had and had not achieved complete discontinuation, and to identify patient and medication characteristics that might predict the outcomes. Our hypothesis was that discontinuation of antipsychotics used for behavioural symptoms would not lead to worsening in behaviour. Methods This was a multi-centre parallel-group study comparing two discontinuation schedules of 14 and 28 weeks. Allocation to the two discontinuation schedules took place in a 1:1 ratio. Antipsychot-

show abstract

“…A recent review outlined that trials in this area generally involved too low numbers of patients with too much heterogeneity to draw conclusions (Scheifes et al . ).…”

Section: Introductionmentioning

confidence: 97%

Effects of controlled discontinuation of long‐term used antipsychotics for behavioural symptoms in individuals with intellectual disability

Kuijper

Evenhuis

Minderaa

et al. 2012

J intellect Disabil Res

View full text Add to dashboard Cite

show abstract

“…Among these prescriptions, those for antipsychotic drugs are the most frequent. Although some studies have shown that antipsychotics may be efficacious in treatments of challenging behaviours, the quality of these studies is generally poor (Deb et al., ; McQuire, Hassiotis, Harrison, & Pilling, ; Scheifes, Stolker, Egberts, Nijman, & Heerdink, ) and serious side effects frequently occur (Bhuvaneswar, Baldessarini, Harsh, & Aplert, ; De Kuijper, Mulder, Evenhuis, Scholte, Visser, & Hoekstra, ; Matson & Mahan, ). Some studies have shown that discontinuation of antipsychotics used for behavioural symptoms is possible without behavioural deterioration (Ahmed et al., ; De Kuijper, Evenhuis, Minderaa, & Hoekstra, ; Sheehan & Hassiotis, ).…”

Section: Introductionmentioning

confidence: 99%

Knowledge and expectations of direct support professionals towards effects of psychotropic drug use in people with intellectual disabilities

Kuijper

Putten

2017

Research Intellect Disabil

View full text Add to dashboard Cite

show abstract

“…The cases illustrate the use of psychotropic drugs from multiple therapeutic classes for the treatment of complex cases of mood dysregulation in ID. Despite being underrepresented in controlled clinical trials of psychotropic drug use for behavioral problems, 52 substantial percentages of adults with ID are reported to receive treatment with psychotropic drugs, particularly combination therapy regimens. In a study of 4069 community-dwelling adults with ID in New York State, 58% were receiving treatment with at least 1 psychotropic medication.…”

Section: Risk/benefit Considerations In Drug Treatment Selectionmentioning

confidence: 99%

Recognition and treatment of mood dysregulation in adults with intellectual disability

Noel

2018

Mental Health Clinician

View full text Add to dashboard Cite

Mood dysregulation is a common feature in the psychopathology of people with intellectual disability (ID) and co-occurring behavioral/psychiatric disorders. It can present with a host of dangerous behaviors, including aggression, self-injury, and property damage. There are special techniques that are used to assess these behaviors in people with ID, that can eventually inform an appropriate approach to pharmacologic and nonpharmacologic treatment. Two case studies are presented that illustrate the elements in the assessment and treatment of mood dysregulation in ID.

show abstract

Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems

Abstract: Studies in which people with ID are included are of a sufficient quality, but of a small size. The heterogeneity in the characteristics of the ID population included as well as in the applied assessment instruments makes performing meta-analyses unfeasible.

Cited by 25 publications

References 115 publications

Effects of controlled discontinuation of long‐term used antipsychotics for behavioural symptoms in individuals with intellectual disability

Effects of controlled discontinuation of long‐term used antipsychotics for behavioural symptoms in individuals with intellectual disability

Knowledge and expectations of direct support professionals towards effects of psychotropic drug use in people with intellectual disabilities

Recognition and treatment of mood dysregulation in adults with intellectual disability

Contact Info

Product

Resources

About